Published in Glycobiology on October 20, 2004
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol (2010) 1.21
Single walled carbon nanotubes as reporters for the optical detection of glucose. J Diabetes Sci Technol (2009) 0.94
Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides. Anal Biochem (2012) 0.85
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors (Basel) (2009) 0.83
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis. Pharmaceuticals (Basel) (2010) 0.80
Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma. World J Gastroenterol (2007) 0.79
Effect of non-anticoagulant N-desulfated heparin on basic fibroblast growth factor expression, angiogenesis, and metastasis of gastric carcinoma in vitro and in vivo. Gastroenterol Res Pract (2012) 0.78
Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. Br J Haematol (2016) 0.75
Identification of heparin modifications and polysaccharide inhibitors of Plasmodium falciparum merozoite invasion that have potential for novel drug development. Antimicrob Agents Chemother (2017) 0.75
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol (2006) 2.57
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Sonographic quantitative evaluation of scrotal veins in healthy subjects: normative values and implications for the diagnosis of varicocele. Eur Urol (2006) 2.17
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des (2007) 2.14
Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem (2005) 2.03
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 1.86
Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood (2010) 1.85
Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res (2007) 1.79
The gelatin sponge-chorioallantoic membrane assay. Nat Protoc (2006) 1.77
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica (2002) 1.69
Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J (2002) 1.61
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem (2006) 1.59
The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc (2007) 1.56
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie (2003) 1.50
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res (2007) 1.48
The role of podoplanin in tumor progression and metastasis. Anticancer Res (2008) 1.48
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res (2004) 1.41
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
A portrait of Aristotle as an anatomist: historical article. Clin Anat (2007) 1.40
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol (2003) 1.39
Mondino de' Liuzzi and his Anothomia: a milestone in the development of modern anatomy. Clin Anat (2006) 1.38
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A (2009) 1.36
A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res (2004) 1.35
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Nerve growth factor as an angiogenic factor. Microvasc Res (2007) 1.32
Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J (2005) 1.32
Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol (2008) 1.30
Analysis of the role of chemokines in angiogenesis. J Immunol Methods (2003) 1.30
The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb (2006) 1.29
Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol (2002) 1.28
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol (2005) 1.27
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol (2005) 1.25
Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood (2004) 1.25
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol (2010) 1.21
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res (2003) 1.21
Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia (2003) 1.21
The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis (2011) 1.20
Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res (2002) 1.16
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res (2009) 1.16
Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 1.15
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 1.15
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J (2007) 1.14
Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem (2003) 1.13
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res (2011) 1.12
Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med (2007) 1.11
Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol (2005) 1.11
Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem (2006) 1.10
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem (2005) 1.09
Piecemeal degranulation as a general secretory mechanism? Anat Rec A Discov Mol Cell Evol Biol (2003) 1.09
Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 1.09
Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost (2007) 1.08
HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis (2002) 1.07
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07